Quick Answer
Anika Therapeutics, Inc. reported Total Revenue of $112.82 million for the year ending 2025.
- Anika Therapeutics, Inc. showed a decrease of -5.9% in Total Revenue from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $23.39 million | Q2 2017: $33.46 million | Q3 2017: $27.18 million | Q4 2017: $29.39 million | Q1 2018: $21.26 million | Q2 2018: $30.55 million | Q3 2018: $26.79 million | Q4 2018: $26.96 million | Q1 2019: $24.72 million | Q2 2019: $30.42 million | Q3 2019: $29.70 million | Q4 2019: $29.77 million | Q1 2020: $35.40 million | Q2 2020: $30.68 million | Q3 2020: $31.69 million | Q4 2020: $32.69 million | Q1 2021: $34.29 million | Q2 2021: $38.15 million | Q3 2021: $39.54 million | Q1 2022: $36.69 million | Q2 2022: $39.66 million | Q3 2022: $40.26 million | Q1 2023: $37.92 million | Q2 2023: $44.30 million | Q3 2023: $41.47 million | Q1 2024: $29.02 million | Q2 2024: $30.72 million | Q3 2024: $29.56 million | Q1 2025: $26.17 million | Q2 2025: $28.22 million | Q3 2025: $27.82 million.
- Over the full 10 years of available data (2016 to 2025), Anika Therapeutics, Inc.'s Total Revenue has grown by 9.1%.
- Historical annual values: Fiscal year 2025: $112.82 million | Fiscal year 2024: $119.91 million | Fiscal year 2023: $120.79 million | Fiscal year 2022: $113.83 million | Fiscal year 2021: $147.79 million | Fiscal year 2020: $130.46 million | Fiscal year 2019: $114.61 million | Fiscal year 2018: $105.56 million | Fiscal year 2017: $113.42 million | Fiscal year 2016: $103.38 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: